Nuvilex, Inc. Strengthens Its Hand in the Cancer Arena With Purchase of Assets

NEW YORK, NY--(Marketwired - Jul 30, 2013) - Nuvilex, Inc. (OTCQB: NVLX) became a much more valuable company in July when it closed a deal it was fully prepared to pay a great deal more money for, but while it spent far fewer dollars, the assets it purchased could prove to fetch a price tag exponentially greater than the $1.5 million the company paid. In addition, Nuvilex originally set aside 100 million of its common shares to negotiate a deal to purchase all of the assets of SG Austria to own those that it wanted; at today's prices the company would have paid close to $20 million versus the $1.5 million it did pay and was able to retain the 100 million shares in doing so. 

By completing the acquisition of Bio Blue Bird AG, the once wholly-owned subsidiary of SG Austria and the owner of the assets Nuvilex coveted, the Silver Spring biotech firm strengthened its hand in the cancer arena, became a legitimate biotech, and now controls an entire technology with regard to its use in any type of cancer treatment. 

Nuvilex now owns exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment it will be using in the company's future Phase III clinical trials. These licenses include worldwide rights to utilize the live-cell encapsulation platform technology to develop treatments for any and all cancer types, regardless of the cell type encapsulated. 

If Nuvilex shows the same success in its future Phase III clinical trials in advanced pancreatic cancer as the data that was presented from the company's two independent Phase II trials, then this gives the small biotechnology company and its shareholders a very powerful hand in the cancer arena. You can bet a lot of eyes are eagerly anticipating the company entering into late-stage trials and the return of the first bits of data from those trials. 

If the company can continue to prove its technology will deliver better results than existing therapy using its proprietary and unique live-cell encapsulation, then big Pharma will take notice and like with stem cells, this form of treatment could open up the flood gates for those larger biotech and pharmaceuticals to add to their pipeline, and we all know cancer research is big business.

Continue reading this article at www.stockmarketmediagroup.com/features.

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors. For more information: www.stockmarketmediagroup.com

This article is the opinion of Stock Market Media Group and was written based upon publicly available information. Nuvilex has not endorsed or compensated Stock Market Media Group for this article.